Literature DB >> 18021214

Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab.

S D Richard1, T C Krivak, S Beriwal, K K Zorn.   

Abstract

Recurrent vulvar carcinoma with metastasis has few effective treatment options, which are mainly directed toward palliation of symptoms. A 70-year-old woman was originally treated in 1999 for vulvar squamous cell carcinoma (SCC) with radical vulvectomy and bilateral inguinofemoral groin dissection. She represented in 2005 with a new lesion distinct from the margin of her first disease occurrence. Although treatment of this area included surgical resection and chemoradiation, she recurred 3 months later. Despite radical surgical resection with an anal perineal resection, she presented 2 months later with widely metastatic disease. Epidermal growth factor receptor (EGFR) staining of the tumor cells showed 3+ staining in 100% of the cells. She was treated with palliative radiation therapy (RT) and a cetuximab plus cisplatin chemotherapy protocol. A partial response was obtained for 5 months with palliation of symptoms. Few treatment options exist for recurrent metastatic vulvar carcinoma. The combination of the EGFR antagonist cetuximab with cisplatin has shown modest success in other metastatic SCCs. The partial response experienced in our patient suggests its potential use in women with recurrent or metastatic vulvar carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18021214     DOI: 10.1111/j.1525-1438.2007.01145.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

1.  Long term response to erlotinib in a patient with recurrent vulvar carcinoma: Case report and review of literature.

Authors:  Hanane Inrhaoun; Ibrahim Elghissassi; Maya Gutierrez; Etienne Brain; Hassan Errihani
Journal:  Gynecol Oncol Case Rep       Date:  2012-07-27

Review 2.  "Unresectable" vulval cancers: is neoadjuvant chemotherapy the way forward?

Authors:  Kathryn Graham; Kevin Burton
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

Review 3.  Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies.

Authors:  Simona Maria Fragomeni; Frediano Inzani; Anna Fagotti; Luigi Della Corte; Stefano Gentileschi; Luca Tagliaferri; Gian Franco Zannoni; Giovanni Scambia; Giorgia Garganese
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-25       Impact factor: 4.553

Review 4.  Chemotherapy of vulvar cancer: a review.

Authors:  Gunter Deppe; Ismail Mert; Jimmy Belotte; Ira S Winer
Journal:  Wien Klin Wochenschr       Date:  2013-03-22       Impact factor: 1.704

5.  Use of Cetuximab in Combination with Cisplatin and Adjuvant Pelvic Radiation for Stage IIIB Vulvar Carcinoma.

Authors:  Jennifer Bergstrom; Michael Bidus; Edward Miles; Jay Allard
Journal:  Case Rep Obstet Gynecol       Date:  2015-07-29

Review 6.  Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview.

Authors:  Riccardo Di Fiore; Sherif Suleiman; Francesca Pentimalli; Sharon A O'Toole; John J O'Leary; Mark P Ward; Neil T Conlon; Maja Sabol; Petar Ozretić; Ayse Elif Erson-Bensan; Nicholas Reed; Antonio Giordano; C Simon Herrington; Jean Calleja-Agius
Journal:  Int J Mol Sci       Date:  2021-04-07       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.